Insights

Gathering insights about Take…

Similar companies to Take

Take Tech Stack

Take uses 8 technology products and services including RSS, Webpack, Select2, and more. Explore Take's tech stack below.

RSS
Content Management System
Webpack
Development
Select2
Javascript Libraries
WPBakery
Page Builders
Yoast SEO
Search Engines
Google Tag Manager
Tag Management
Google Analytics
Web Analytics
Astra
Web Platform Extensions

Media & News

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood.
Jan 05, 2026 | www.businesswire.com
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial intelligence, succeeded in two late-stage studies.
Dec 18, 2025 | www.reuters.com
Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment.
Dec 18, 2025 | www.businesswire.com
Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review
Siga Technologies (NASDAQ: SIGA - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk. Analyst Recommendations This is a summary of current
Dec 15, 2025 | www.defenseworld.net
Takeda Pharmaceutical Co. $TAK Shares Sold by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 13.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,218,690 shares of the company's stock after selling 181,766 shares during the period.
Dec 08, 2025 | www.defenseworld.net
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide's efficacy and safety and demonstrate du.
Dec 06, 2025 | www.businesswire.com
Fisher Asset Management LLC Acquires 46,490 Shares of Takeda Pharmaceutical Co. $TAK
Fisher Asset Management LLC raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 89.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,635 shares of the company's stock after acquiring an additional 46,490 shares during the quarter. Fisher
Dec 06, 2025 | www.defenseworld.net

Take's Email Address Formats

Take uses at least 1 format(s):

Take Email Formats	Example	Percentage
First.Last@takeandgoapp.com	John.Doe@takeandgoapp.com	43%
First@takeandgoapp.com	John@takeandgoapp.com	7%
First.Last@takeandgoapp.com	John.Doe@takeandgoapp.com	43%
First@takeandgoapp.com	John@takeandgoapp.com	7%

Frequently Asked Questions

What is Take's stock symbol?

Take is a publicly traded company; the company's stock symbol is TAK.

What is Take's official website and social media links?

Take's official website is takeandgoapp.com and has social profiles on LinkedIn Crunchbase.

What is Take's NAICS code?

Take's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Take have currently?

As of December 2025, Take has approximately 74 employees across 6 continents, including South AmericaEuropeAsia. Key team members include Cto: V. V.Chief Sales Officer: E. C.Head De Engenharia: T. F. D. S.. Explore Take's employee directory with LeadIQ.

What industry does Take belong to?

Take operates in the IT Services and IT Consulting industry.

What technology does Take use?

Take's tech stack includes RSSWebpackSelect2WPBakeryYoast SEOGoogle Tag ManagerGoogle AnalyticsAstra.

What is Take's email format?

Take's email format typically follows the pattern of First.Last@takeandgoapp.com. Find more Take email formats with LeadIQ.

How much funding has Take raised to date?

As of December 2025, Take has raised $1M in funding. The last funding round occurred on Aug 24, 2021 for $1M.

When was Take founded?

Take was founded in 2020.

Take

Q: What is Take's official website and social media links?

Take's official website is takeandgoapp.com. Take has social profiles on LinkedIn.

Q: How many employees does Take have currently?

Take has approximately 74 employees.

Q: What technology does Take use?

Take's tech stack includes RD Station, Apache HTTP Server, Node.js, Font Awesome, jQuery.

IT Services and IT ConsultingSão Paulo, Brazil51-200 Employees

A Take aplica tecnologia de ponta e combina Automação + Inteligência Artificial para proporcionar nova experiência de compra através da hiperconveniência.

Company Overview

Website: takeandgoapp.com
Stock Symbol: TAK
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2020
Employees: 51-200

Media & News

Funding & Financials

$1M
Take has raised a total of $1M of funding over 1 rounds. Their latest funding round was raised on Aug 24, 2021 in the amount of $1M.
$1M
Take's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
Take has raised a total of $1M of funding over 1 rounds. Their latest funding round was raised on Aug 24, 2021 in the amount of $1M.
$1M
Take's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Take

DELTA

Alpha Solutions A/S

Gamma Group

Take Tech Stack

Media & News

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda's AI-crafted psoriasis pill succeeds in late-stage studies

Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda Pharmaceutical (NYSE:TAK) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head Review

Takeda Pharmaceutical Co. $TAK Shares Sold by Arrowstreet Capital Limited Partnership

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Fisher Asset Management LLC Acquires 46,490 Shares of Takeda Pharmaceutical Co. $TAK

Take's Email Address Formats

Frequently Asked Questions

What is Take's stock symbol?

What is Take's official website and social media links?

What is Take's NAICS code?

How many employees does Take have currently?

What industry does Take belong to?

What technology does Take use?

What is Take's email format?

How much funding has Take raised to date?

When was Take founded?

Take

Company Overview

Media & News

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda's AI-crafted psoriasis pill succeeds in late-stage studies

Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?